In a report released yesterday, Josh Jennings from TD Cowen maintained a Hold rating on Becton Dickinson (BDX – Research Report), with a price ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

Wednesday, analysts at TD Cowen increased their price target on Fiserv (NYSE:FI) shares from $235.00 to $277.00, while retaining a Buy rating on the stock. The stock, currently trading at $229.53, has ...

In a report released today, William Katz from TD Cowen maintained a Hold rating on Artisan Partners (APAM – Research Report), with a price ...

Arthur J. Gallagher & Co. (AJG) stock saw a modest uptick, ending the day at $312.21 which represents a slight increase of $3.21 or 1.04% from the prior close of $309. The stock opened at $309 and ...

OSI Systems, Inc. (NASDAQ: OSIS), today announced that it will present at the TD Cowen 46th Annual Aerospace & Defense Conference on Wednesday, February 12, 2025, at 10:45 AM ET.

The transportation sector will be impacted by Trump's new tariff regime. Parcel consolidators and freight forwarders - like ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 2.59% of ...

Noting that Ambry is a profitable testing laboratory that generates more than $300 million of revenue annually, the investment bank thinks that the deal will enable TEM to start generating positive ...

Johnson & Johnson (NYSE: JNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will participate in a fireside chat at 11:10 a.m. Eastern Time.

TD Cowen expressed concerns about valuation. “If Celsius can’t demonstrate a path back to growth, it could end up being valued at a multiple more similar to other ex-growth CPG companies,” the note ...

TD Cowen initiated coverage of KalVista (KALV) with a Buy rating and $30 price target The firm cites sebetralstat’s opportunity as the first oral acute therapy for hereditary angioedema attacks ...